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Patients with chronic liver disease and certain patients with acute liver failure require liver transplantation as a life-saving measure.
Liver transplantation has undergone major improvements, with better selection of candidates for transplantation and allocation
of scarce deceased donor organs (according to more objective criteria). Living donor liver transplantation came into existence
to overcome the shortage of donor organs especially in countries where there was virtually no deceased donor programme.
Advances in the technical aspects of the procedure, the intraoperative and postoperative care of both recipients and donors,
coupled with the introduction of better immunosuppression protocols, have led to graft and patient survivals of over 90% in
most high volume centres. Controversial areas like transplantation in alcoholic liver disease without abstinence, acute alcoholic
hepatitis, and retransplantation for recurrent hepatitis C virus infection require continuing discussion.
1.Introduction
Liver transplantation is a life-saving procedure for patients
withchronicendstageliverdiseaseandselectedpatientswith
acute liver failure (ALF) [1–3]. Over the years, the technique
of the operation has undergone major changes. Together
with this, there has been an improvement in the understand-
ing of pre- and posttransplantation physiology and the
introduction of newer and more eﬀective immunosuppres-
sive drugs and strategies for preventing posttransplantation
infections so that, in the United States, the one year patient
survivalhasnowreached87.6%andgraftsurvival82.4%[4].
Liver grafts for transplantation can be obtained either
from deceased donors (DDs) or living donors (LDs).
Living donor liver transplantation (LDLT) was introduced
because of the increasing demand for donor organs and
the widening gap between the resource (deceased donor)
and demand (recipient). It is very important to prioritize
the patients for organ allocation in a deceased donor
liver transplantation (DDLT) programme. This is, however,
diﬀerent in a programme which is based mainly on LDLT
where the prospective donor is usually a close relation.
However, in both the situations, a measure such as a sco-
ring system is important in prognosticating the outcome
following transplantation. There has to be a balance between
the patient’s medical reserves to withstand a major operation
like liver transplantation and its probable outcome.
For DDLT organ, allocation was initially based on the
locationofthepatient(athome,inhospitalorinanintensive
care unit) and the time on the waiting list (United Network
for Organ Sharing-UNOS status). However, with the use
of more objective mathematical models, based on certain
selected risk factors such as the model for end-stage liver
disease (MELD) score, the system of allocation has probably
improved. The MELD and PELD (for paediatric recipients)
scoresaresystemsforassessingapatient’sneedfortransplan-
tationorforthelikelihoodofrequiringtransplantationinthe
future [5–7].
The older Child-Turcotte-Pugh (CTP) classiﬁcation sys-
tem and its variations have also been used to stratify patients
with chronic liver disease to predict the mortality and
morbidity. However, because it relies on many subjective
criteria, its use has been superseded by the MELD and
PELD scores. These are mathematical regression models
which objectively assess the need for liver transplantation
and more accurately predict the short-term mortality while
on the transplantation waiting list. Their purpose is to help
physicians select those patients who might beneﬁt most from2 International Journal of Hepatology
Table 1: United network for organ-sharing (UNOS) liver status classiﬁcation.
Status 1
Fulminant liver failure with life expectancy <7d a y s
(i) Fulminant hepatic failure as traditionally deﬁned
(ii) Primary graft nonfunction <7 days of transplantation
(iii) Hepatic artery thrombosis <7 days of transplantation
(iv) Acute decompensated Wilson’s disease
Status 2a
Hospitalized in ICU for chronic liver failure with life expectancy <7 days, with a Child-Pugh score of ≥10 and one of the
following:
(i) unresponsive active variceal hemorrhage
(ii) hepatorenal syndrome
(iii) refractory ascites/hepatic hydrothorax,
(iv) Stage 3 or 4 hepatic encephalopathy
Status 2B
Requiring continuous medical care, with a Child-Pugh score of ≥10, or a Child-Pugh score ≥7 and one of the following:
(i) unresponsive active variceal hemorrhage
(ii) hepatorenal syndrome
(iii) spontaneous bacterial peritonitis
(iv) refractory ascites/hepatic hydrothorax,
or presence of hepatocellular carcinoma
Status 3 Requiring continuous medical care, with a Child-Pugh score of ≥7, but not meeting criteria for Status 2B
Status 7 Temporary inactive
From http://www.unos.org/ initially implemented in July 1997 later modiﬁed in January 1998 and August 1998.
the transplantation. The MELD score is calculated using the
patient’sinternationalnormalizedratio(INR),bilirubin,and
creatinine according to the formula given below [8, 9].
MELD score = 10{0.957 log(serum creatinine) + 0.378
log(total bilirubin) + 1.12 log(INR) + 0.643}
If the MELD score is ≥30 the patient’s UNOS listing
status (Table 1) is 2a, if it is 24–29, it is 2b, and if it is less
than 24, it is 3.
The PELD score includes parameters like albumin,
bilirubin, INR, age (<1y e a r ,>1 year), and the presence of
growth failure to stratify children with liver disease on the
waiting list.
2. Timing of Referral
Patients with a MELD score of >10 and/CTP score of >7a r e
referred for transplantation [10]. Other criteria to take into
consideration are those with decompensated chronic liver
disease in the form of intractable ascites, spontaneous bac-
terial peritonitis, variceal bleeding, encephalopathy, jaundice
as well as health-related quality of life issues such as severe
itching and recurrent cholangitis. Conditions which are not
included in the scoring system and inﬂuence allocation
are hepatocellular carcinoma, hepatopulmonary syndrome,
and portopulmonary hypertension (Tables 2 and 3). Organ
allocation is according to the status of the patient (UNOS
status) and the MELD/PELD score. A Status 1 (Table 1)
patient is given priority following which those with a
MELD/PELD score ≥15 and later those having a score of
≤14.
3. Indications for LiverTransplantation
The list of indications for liver transplantation includes all
the causes of end stage liver disease which are irreversible
and curable by the procedure (Tables 2 and 3). In 1997
the American Society of Transplant Physicians and the
American Association for the Study of the Liver Disease
put forward the minimal listing criteria for patients with
end stage liver disease. To qualify for the listing, the
patient’s expected survival should be ≤90% within 1 year
without transplantation. Liver transplantation should lead
to prolonged survival and an improved quality of life
[10]. The outcome following liver transplantation is better
for those with chronic cholestatic liver disease (including
primary biliary cirrhosis and primary sclerosing cholangitis)
compared with those who have hepatocellular carcinoma.
3.1. Acute Liver Failure (ALF). Fulminant hepatic failure
(ALF and subfulminant hepatic failure) is characterized by
encephalopathy, jaundice, and coagulopathy. It accounts for
5-6% of all patients undergoing liver transplantation [4]. In
the West, acetaminophen toxicity is the leading cause of ALF,
and hepatitis A, E, B and seronegative hepatitis are the other
common aetiological factors. The major cause of subfulmi-
nant hepatic failure is idiosyncratic drug induced liver injury
[11].PatientswhomeettheKing’sCollegeCriteriaforurgent
transplantation provide a very small window for action, and
they need to undergo transplantation, as soon as possible.
There is a 100% percent mortality if these selected patients
do not undergo transplantation and this is either due to liverInternational Journal of Hepatology 3
Table 2: Indications for liver transplantation.
Acute liver failure
Hepatitis A, acetaminophen, autoimmune hepatitis
Hepatitis B
Hepatitis C, cryptogenic
Drugs, hepatitis D
Wilson’s disease, Budd-Chiari syndrome
Fatty inﬁltration—acute fatty liver of pregnancy, Reye’s syndrome
Cirrhosis from chronic liver disease
Chronic hepatitis B virus infection
Chronic hepatitis C virus infection
Alcoholic liver disease
Autoimmune hepatitis
Cryptogenic liver disease
Nonalcoholic fatty liver disease
Malignant diseases of the liver
Hepatocellular carcinoma
Carcinoid tumor
Islet cell tumor
Epithelioid hemangioendothelioma
Cholangiocarcinoma
Metabolic liver disease
Wilson’s disease
Hereditary hemochromatosis
Alpha-1 antitrypsin deﬁciency
Glycogen storage disease
Cystic ﬁbrosis
Glycogen storage disease I and IV
Crigler-Najjar syndrome
Galactosemia
Type 1 hyperoxaluria
Familial homozygous hypercholesterolemia
Hemophilia A and B
Vascular diseases of the liver
Budd-Chiari syndrome
Veno-occlusive disease
Cholestatic liver diseases
Primary biliary cirrhosis
Primary sclerosing cholangitis
Secondary biliary cirrhosis
Biliary atresia
Alagille syndrome
Byler’s disease
Miscellaneous
Adult polycystic liver disease
Nodular regenerative hyperplasia
Caroli’s disease
Severe graft-versus-host disease
Amyloidosis
Sarcoidosis
Hepatic trauma
Table 3: Variant syndromes requiring liver transplantation.
Intractable ascites
Diuretic resistant, Nonresponsive to TIPS or, TIPS
contraindicated
Hepatopulmonary Syndrome
Shunt fraction >8%, pulmonary vascular dilatation
Chronic hepatic encephalopathy
Persistent and intractable pruritus
failure per se or because of sepsis and multiorgan failure
[11]. Patients with subacute failure have a poor outcome
with almost universal mortality if not transplanted; these
patients might require transjugular liver biopsy to establish
the presence of massive or submassive liver cell necrosis.
Timely referral is important in these patients because in the
absence of transplantation death may occur from sepsis and
cerebral oedema. There are several scoring systems for listing
a patient for urgent liver transplantation: King’s College
criteria, UK Blood and Transplant criteria, Clichy criteria
(acute viral hepatitis), and Wilson’s prognostic index/revised
Wilson’s prognostic index (Wilson’s disease with fulminant
hepatitis) [12–16]. (Tables 4 and 5).
3.2. Chronic Liver Disease. Patients who have a projected
1-year mortality of 10% without liver transplantation get
entry into the waiting list. Apart from their CTP and MELD
scores, the UK Liver Transplant Units have developed a new
scoring system to predict the mortality of such patients. This
is the United Kingdom model for end-stage liver disease
(UKELD) score—which is calculated by using the patient’s
serum bilirubin, INR, creatinine, and sodium levels [17].
Patients with a UKELD score of more than 49 fall into the
criteria for listing. This score is dynamic and is reassessed
over a period of time.
3.3. Alcoholic Liver Disease (ALD). A patient with ALD who
is abstinent for a period of at least 3–6 months and who
has had an evaluation with a psychiatrist is listed for trans-
plantation if he has a CTP score of ≥7, portal hypertensive
bleed, or an episode of spontaneous bacterial peritonitis
[18]. These patients may have a concurrent infection with
hepatitis B or C virus which needs evaluation. They are also
more prone to develop hepatocellular carcinoma. A period
of abstinence is mandatory to ensure that they do not relapse
and also to give a trial of an alcohol-free period during which
the liver function might recover. The period of abstinence
is not uniform, however, but presently a 6-month rule of
abstinence is generally followed in US and European liver
transplant programmes [19].
Acute alcoholic hepatitis (AAH) is a contra-indication
for liver transplantation as the required period of abstinence
is lacking, and there is very little and mixed experience of
liver transplantation in this situation. The severity of AAH
is assessed using the Maddrey discriminant function (DF)
score which predicts the risk of early death. Patients with a
DF score of ≥32 are put on medical therapy [20, 21]. There4 International Journal of Hepatology
Table 4: UK blood and transplant criteria for registration as a super-urgent transplant.
Paracetamol poisoning
Category 1 pH < 7.25 more than 24 hours after overdose and ﬂuid resuscitation
Category 2 Coexisting prothrombin time >100s or INR > 6.5 and serum creatinine >300μmol/L or anuria, and grade 3-4 en
encephalopathy
Category 3 Serum Lactate >24 hours after overdose > 3.5mmol/L on admission or >3mmol/L after ﬂuid resuscitation
Category 4 Two of the three criteria from category 2 with clinical evidence of deterioration (e.g. increased ICP, Fi02 > 50%,
increasing inotrope requirement) in the absence of clinical sepsis
Seronegative hepatitis, hepatitis A, B, or an idiosyncratic drug
reaction
Category 5 Prothrombin time >100s or INR > 6.5, and any grade of encephalopathy
Category 6
Any grade of encephalopathy, and any three from the following: unfavourable aetiology (idiosyncratic drug reaction,
seronegative hepatitis), age > 40 years jaundice encephalopathy interval >7 days, serum bilirubin >300μmol/L,
prothrombin time >5 0so rI N R> 3.5
Category 7 Acute presentation of Wilson’s disease, or Budd-Chiari syndrome. A combination of coagulopathy, and any grade of
encephalopathy
Category 8 Hepatic artery thrombosis on days 0 to 21 days after liver transplantation
Category 9 Early graft dysfunction on days 0 to 7 after liver transplantation with at least 2 of the following: AST > 10,000IU/L, INR
> 3.0, serum lactate > 3mmol/L, absence of bile production
Category 10 Any patient who has been a live donor who develops severe liver failure within 4 weeks of the donor operation
Table 5: Criteria for liver transplantation in acute liver failure (ALF).
(a) King’s College Criteria
Acetaminophen-induced ALF Nonacetaminophen ALF
(1) Arterial pH < 7.3 irrespective of grade of encephalopathy (1) INR > 6.5 (PT > 100sec), irrespective of grade of
encephalopathy
OR OR any 3 of the following:
(1) PT > 100sec (1) INR > 3.5 (PT > 50sec)
(2) Serum creatinine >3.4mg/dL (2) Age < 10 or >40 years
(3) Stage 3 or 4 encephalopathy (3) Serum bilirubin >18mg/dL
(4) Jaundice to encephalopathy interval >7d a y s
(5) Non-A, non-B hepatitis, idiosyncratic drug reaction
(b) Prognostic index in fulminant Wilsons hepatitis (WPI) [14]
S c o r e 0 123 4
Serum bilirubin (reference range 3–20mmol/L) <100 100–150 151–200 201–300 >300
Serum aspartate transaminase (reference range 7–40IU/L) <100 100–150 151–200 201–300 >300
Prothrombin time prolongation (seconds) <4 4–8 9–12 13–20 >30
Patients with a WPI score ≥7 need urgent liver transplantation
(c) Revised Wilson prognostic index (RWPI) [15]
Score Bilirubin (μmol/L) INR AST (IU/L) WCC (109/L) Albumin (g/L)
0 0–100 0–1.29 0–100 0–6.7 >45
1 101–150 1.3–1.6 101–150 6.8–8.3 34–44
2 151–200 1.7–1.9 151–300 8.4–10.3 25–33
3 201–300 2.0–2.4 301–400 10.4–15.3 21–24
4 ≥301 >2.5 >401 >15.4 <20
Patients with a RWPI ≥11 needed urgent liver transplantation
(d) Clichy criteria (Hospital Paul-Brousse, Villejuif [16])
Hepatic encephalopathy, and factor V level:
<20% in patients <30 years of age, or
<30% in patients ≥30 years of ageInternational Journal of Hepatology 5
have been recent reports from France where transplantation
is being proposed for patients with AAH; however, it is still
not accepted as an indication elsewhere [22].
3.4.ViralHepatitis. HepatitisCvirus(HCV)-relatedchronic
liver disease is the commonest indication for liver transplan-
tation in the United States [23]. It is important to know
the pretransplant viral load and genotype; this helps in
predicting the prognosis after transplantation. Patients with
decompensatedHCV-relatedchronicliverdiseasedonottol-
erate interferon therapy, and those with high viral loads have
ahighchanceofrecurrenceinthenewgraft.Accordingtothe
InternationalLiverTransplantationSociety(ILTS)guidelines
patients with a child’s score of 8–11 may be considered for
antiviral treatment while they are listed for transplantation;
however, there are very high chances of adverse events [24].
Posttransplantation serological recurrence is universal in
patients who have viraemia at the time of transplantation.
P a t i e n ts u r v i v a li sa d v e r s e l ya ﬀected by the pretransplant
viral load and cytomegalovirus status, advanced recipient
age, hyperbilirubinaemia, a raised INR, and advanced donor
age [25]. Retransplantation in these patients with recurrent
HCV infection and cirrhosis is controversial in the setting
of DDLT. The eﬃcacy of antiviral therapy in the presence
of a recurrence is questionable. Patients with early (within
one year) aggressive recurrence and graft failure have a poor
outcome following retransplantation.
Hepatitis B virus-related chronic liver disease is another
common indication for transplantation, and this was pre-
viously also associated with a high prevalence of recurrent
infection in the graft. However, the availability of hepatitis B
immunoglobulin (HBIG) and oral nucleoside or nucleotide
therapy reinfection of the graft and recurrent hepatitis B
disease is rare. The duration of HBIG therapy and oral
antiviral therapy is still controversial; a few programmes
give HBIG for one year while others are using it life long
[26].
3.5. Cholestatic Liver Disease. The severity of cholestatic liver
diseases such as primary biliary cirrhosis(PBC) and primary
sclerosingcholangitis (PSC)istakeninto considerationapart
from using the child’s score (≥7) and the Mayo models
for PSC and PBC with a risk score predicting > than
10% mortality at one year without transplantation [10].
Quality of life issues like recurrent cholangitis requiring
repeated drainage procedures (endoscopic or percutaneous),
intractable itching, xanthomatous neuropathy, and severe
metabolic bone disease are some of the other indications for
transplantation.
In paediatric patients, biliary atresia and sclerosing cho-
langitis are the commonest cholestatic disorders requiring
transplantation, with biliary atresia being the foremost cause
(60–70%) in those undergoing liver transplantation [27].
Liver transplantation is required in most patients with
biliary atresia irrespective of a previous Kasai’s procedure.
Other cholestatic disorders which can lead to cirrhosis
and decompensation requiring transplantation are the Alag-
ille syndrome and Byler’s disease.
3.6. Hepatic Malignancy. Cirrhosis is associated with a 2 to
8% annual incidence of hepatocellular carcinoma [28]. Liver
transplantation has become the mainstay of treatment for
HCC in the early stages, as it oﬀers the advantage of not
only being curative, thus, minimizing the risk of recurrence;
it also takes care of the complications associated with the
underlying cirrhosis. There have been several criteria for
listing these patients for transplantation. They have been
modiﬁed over a period of time so as to include as many
patients who would beneﬁt from transplantation and who
would have a 5-year survival of >50%. The Milan criteria
deﬁnes early stage HCC as those with a single lesion <
5cm, or no more than 3 lesions, with none > than 3cm,
in the absence of vascular invasion and metastases [29].
However, using the University of California, San Francisco,
(UCSF) criteria (a single lesion ≤6.5cm or 3 or fewer lesions
with the largest being ≤4.5cm and a total tumour burden
of 8cm or less), patients had a similar outcome following
transplantation compared to those within the Milan criteria
[30]. The MELD score in patients with HCC might be
low, and this might prevent these patients from being given
priority or even being listed in spite of the fact that their
disease is fatal if left untreated. Because this these patients
are prioritized depending upon the stage of the tumour,
those with T1 lesions are given a score of 20, and T2 lesions
as c o r eo f2 4[ 31]. While waiting for transplantation, they
usually undergo either transarterial chemoembolisation or
radiofrequency ablation as a “bridge” to more deﬁnitive
therapy.
Other uncommon primary malignancies of the liver
which are indications for transplantation are epitheloid
haemangioendothelioma and hepatoblastoma. Metastatic
lesions of the liver have a poor prognosis; hence, they do not
form an indication for transplantation; however, neuroen-
docrine tumors after the removal of the primary may have a
good outcome following the procedure.
3.7. Metabolic Liver Disease. Metabolic liver diseases which
cause decompensation and irreversible damage are indica-
tions for transplantation. These include Wilson’s disease,
hereditary haemochromatosis, and α1-antitrypsin disease.
They also aﬀect other organ systems; hence, pretransplant
evaluation includes assessment of the concerned system to
rule out systemic disease which would otherwise preclude
transplantation. Other metabolic disorders, which aﬀect
extrahepatic organs while the synthetic liver functions are
intact like Type-1 hyperoxaluria or familial homozygous
hypercholesterolaemia, are indications for transplantation
as the concerned metabolic disorder gets corrected. In
childhood,themetabolicdisorderswhichformanindication
for transplantation are the urea cycle defects, Criggler-Najjar
syndrome, tyrosinaemia, and cystic ﬁbrosis.
3.8. Vascular Disorders. The Budd-Chiari syndrome is char-
acterized by obstruction to the hepatic venous outﬂow either
at the level of the hepatic veins and/or the inferior vena
cava.Itisassociatedwithmyeloproliferativedisorders(50%),
malignancy (10%), hypercoagulable states (15%), webs in6 International Journal of Hepatology
the IVC, and paroxysmal nocturnal haemoglobinuria (5%).
No cause is found in about 20% of patients. Indications for
transplantationinthesepatientsareestablishedcirrhosisand
acute decompensation. These patients generally require life-
long anticoagulation after the transplant procedure [32].
3.9. Miscellaneous. Complicated polycystic liver disease
(combined with or without kidney disease) with haemor-
rhage, infection, pain, massive cystic enlargement, portal
hypertension, biliary obstruction, and rarely malignant
transformation also forms an indication for liver transplan-
tation. These patients might have well-preserved synthetic
functions. Auto immune hepatitis (AIH) either alone or as
anoverlapsyndromewithPSC/PBCisanotherindicationfor
transplantation. It is important to identify the AIH as these
patients require life-long low-dose steroids. Nonalcoholic
steatohepatitis is another cause of cirrhosis which might
require transplantation.
4. Contraindications to LiverTransplantation
4.1. Severe Cardiopulmonary Disease. Severe pulmonary
hypertension or hypoxaemia resulting from the hepatopul-
monary syndrome (HPS) poses an undue risk to patients at
the time of transplantation (Table 6). A mean pulmonary
arterial pressure (PAP) of ≥50mmHg is an absolute contra-
indicationfortransplantationasthepostproceduremortality
is 100%. Those with PAP between 35–50mmHg have a
50% mortality after transplantation. Patients with mild
pulmonary hypertension with a mean PAP of <35mmHg
are suitable candidates [33]. The mortality in patients with
HPS increases to about 30% in the presence of arterial
hypoxaemia (<50mmHg PaO2)[ 34]. Oxygen-dependent
chronicobstructiveairwaysdiseaseandadvancedpulmonary
ﬁbrosis are contraindications for transplantation, whereas
reactive airway disease, hepatic hydrothorax, muscle wasting
and infection, being reversible conditions, are only relative
contraindications.
Symptomatic coronary artery disease, severe ventricular
dysfunction,advancedcardiomyopathy,severevalvularheart
disease, and aortic stenosis having poor ventricular function
areabsolutecontraindicationsfortransplantation.Following
bypass surgery or revascularization and angioplasty wherein
myocardial ischaemia is resolved, these patients could be
listed for transplantation.
4.2. Active Alcohol and Substance Abuse. Active alcohol
intake or substance abuse is absolute contraindication for
transplantation. A pretransplant period of abstinence is a
must for listing in most transplant programmes, but the
period of abstinence is not well deﬁned (6 months is
generally required) [35]. This period of abstinence gives time
for the acute insult on the liver to recover (if at all some
recovery takes place); it also provides an opportunity for
psychosocial assessment and preparation to minimize the
chance of recidivism following transplantation. About 20–
26% of patients resume heavy alcohol intake within 4.5 years
Table 6: Contraindications to liver transplantation.
Absolute contraindications
Severe cardiopulmonary disease
Extrahepatic malignancy (oncologic criteria for cure not met)
Active alcohol/substance abuse
Acute alcoholic hepatitis
Active infection/uncontrolled sepsis
Lack of psychosocial support/inability to comply with medical
treatment
Brain death
Relative contraindications
Advanced age
Acquired immune deﬁciency syndrome
Cholangiocarcinoma
Diﬀuse portal vein thrombosis
of transplantation; this aﬀects the graft survival adversely
[36].
Acute alcoholic hepatitis is a contraindication for trans-
plantation in almost all programmes. There is insuﬃcient
data on the outcome of transplantation in these patients as
there is no period of abstinence [20, 21].
Itisessentialtoruleoutdrugorpolydrugabuse(opiates,
sedatives, and cannabinoids), active tobacco abuse, as they
form a high-risk group requiring psychiatric assessment and
treatment. These candidates have a relative contraindication
to be listed for transplantation as long as the active abuse
continues.
4.3. Psychosocial Support. Patients following transplantation
require good social support, in the absence of which it is
likely that there will be lack of compliance with the im-
munosuppressive medication leading ultimately to the loss
of the graft.
4.4. Age. Advanced age is associated with cardiopulmonary
risk factors. Older patients require extensive evaluation to
rule out the absolute contraindications like severe cardiopul-
monary disease and malignancy. Patients over the age of
60–65 have been shown to have lower survival rates at 1
year and 5 years than those who are younger [37]. However,
many centres now accept 70 years as the cut oﬀ limit for
transplantation and have shown good results with this policy
[38].
4.5. Obesity. Morbidly obese patients (BMI > 40) have an
increased 5-year mortality after transplantation because of
theassociatedcardiovascularmorbidity[39].Recipientswho
have a BMI > 35kg/m2 require an individualized approach
according to the policy of the centre.
4.6. HIV Infection. Patients with HIV infection have a better
survivalduetotheeﬀectivenessofhighlyactiveantiretroviral
therapy (HAART). However they have other complications
which may prove fatal, like chronic hepatitis C and cirrhosis.International Journal of Hepatology 7
Earlier HIV used to be an absolute contraindication for
transplantation, due to the fear of progression of disease
with immunosuppression; however, with the availability
of highly eﬀective antiretroviral drugs, virus control has
improved and transplantation is now being oﬀered selec-
tively. The absolute contraindication to transplantation in
these patients includes uncontrolled HIV disease with multi
drugresistance, leukoencephalopathy, advanced malnutri-
tion, life support requirement, and opportunistic infections
[26]. Transplantation in these patients should be done
in collaboration with experts in the management of HIV
infections.
4.7. Other Infections. Pneumonia, sepsis, bacteraemia, oste-
omyelitis, and fungal infection should be treated adequately
before transplantation and the ongoing presence of any of
these is an absolute contra-indication.
4.8. Miscellaneous. Retransplantation for recurrent HCV
infection,autoimmunehepatitis,alcoholicliverdisease,non-
alcoholic steatohepatitis, and hepatocellular carcinoma are
some of the controversial areas though not contraindications
in themselves. This is because the survival of both patient
andgraftissuboptimalinthelongterm.Previousabdominal
surgery increases the length of operation, blood loss, and
complications related to the transplantation procedure.
Portal vein thrombosis, once considered to be a contraindi-
cation, is no longer so except in the presence of diﬀuse
thrombosis [40]. Patients with extrahepatic malignancy
require at least a 5-year tumour-free interval before being
considered for transplantation [41]. Cholangiocarcinoma
once an indication for liver transplantation is now a relative
contraindication because of the poor outcome especially in
those with advanced disease.
5.DelistingCriteria
While waiting for the graft, if the liver disease progresses to
such an extent that the survival beneﬁt from transplantation
(50% 5 year survival) no longer holds, which generally
occurs if the MELD score is >40, then it is probably better
to delist the patient. However, there is no guideline as
such for delisting candidates except in patients with HCC
who develop metastatic disease and fall out of the listing
criteria. Patients who resume alcohol intake or substance
abuse should be delisted. Temporary deactivation is done
for patients who have clinical deterioration in the form
of mechanical ventilation, haemodialysis, and fungal or
resistant bacterial infection.
6. LivingDonor LiverTransplantation
The indications for liver transplantation and the criteria for
listing generally remain the same (child’s score ≥7, MELD
>10). Patients with cholestatic liver disease who have lower
MELD scores, but other issues like, recurrent cholangitis,
recurrent encephalopathy, and severe itching, who might not
get listed in a DDLT program may, however, gain entry into
thelistinanLDLTsetting.Thesepatientsbeneﬁtfrompartial
liver grafts as they have otherwise stable liver disease. Studies
have revealed that the average MELD score in a patient
having LDLT is less than the score of a DDLT recipient (14.8
versus 23.5) [8]. The risk of transplantation is increased
compared with its beneﬁt if the MELD score is <14 or more
than 25 [8]. There are two situations where LDLT poses an
a d d e da d v a n t a g eo v e rD D L T .T h eﬁ r s ti sap a t i e n tw i t hH C C
who probably has a lower MELD score, the waiting period is
reduced, and the outcome is equally good. Patients fulﬁlling
theMilanorUCSFcriteria,dependingupontheprogramme,
get transplanted earlier in an LDLT setting before metastases
occur. The other patients who have low MELD scores
and would beneﬁt from LDLT are those with symptomatic
benign liver lesions (haemangioma, haemagioendothelioma,
and polycystic liver disease), metabolic disorders (familial
amyloidosis, hyperoxaluria, tyrosinaemia, glycogen storage
disease), or complicated cholestatic liver disease. These
patients otherwise would have to wait for a longer period to
get a deceased donor graft.
The advantages of LDLT are that almost all transplants
are planned and elective (except for those with ALF), the
recipient’s functional status can be optimized before surgery,
and the graft cold ischaemia time is reduced. There has been
evolution in the donor and patient selection, along with
improvement in the surgical technique in both the donor
and recipient surgery in LDLT. This has led to improved 1-
year graft and patient survival to 81 and 89%; the vascular
and biliary complications have reduced (hepatic artery
thrombosis <5%, biliary complications 5–20%) [42–45].
It is very important to ensure donor safety in an LDLT
program, and so far the reported donor mortality is <0.2–
0.5%, morbidity is between 10–15%, and donor biliary
complication is <5% [42, 46].
7. Contraindications for LDLT
Apart from the contraindications already mentioned in the
earliersection,theadditionalcontraindicationspertainingto
the living donor are as stated below.
Absolute Contraindications.
(1) Donor having macrosteatosis (>20%) on liver biopsy
are rejected.
(2) Remnant liver volume less than 25%. This is an issue
especially when right lobe graft is big. It is never an
issue when the left lateral segment is the proposed
graftandisrarelyanissueiftheleftlobegraftistaken.
(3) The Human Organ Transplantation Act, in India,
does not allow unrelated donation; this is to prevent
donation under any kind of coercion and to avoid
any organ trade. However unrelated donation is
acceptable in other countries like Hong Kong, Korea,
China, Japan, and so forth.
(4) Living donor should be between 18 and 55 years of
age. Lower limit is the age at which legal consent can
be given.8 International Journal of Hepatology
Relative Contraindications.
(1) Body mass index >30 of the donor is generally associ-
ated with macrosteatosis, such donors are advised to
reduce weight, and they need to have a liver biopsy to
rule out >20% steatosis. If there are other potential
donors in the family, they are rejected as liver donors.
(2) Liver attenuation index of <5 on plain CT scan is
suggestive of steatosis; hence, such donors are either
rejected or in the absence of other donors need to
reduce weight and have a biopsy to rule out >20%
macrosteatosis.
(3) Donors are rarely rejected on anatomical grounds.
Double artery, double portal vein, or more than 2
hepatic veins can be easily tackled during implanta-
tion, and these no longer preclude donation. How-
ever, certain anatomical anomalies, for example, a
Type E portal vein in the donor where there are
multiple right-sided segmental portal vein tributaries
draining into the left portal vein is a contraindication
for LDLT [47].
(4) Alltypesofbiliaryanatomyinthedonor(asclassiﬁed
by Huang) is acceptable [48]. Very rarely if there are
multiple ducts in the donor (more than 3 bile ducts)
to be anastomosed, then the donor is rejected [45].
8. Summary
Survival after liver transplantation has progressively im-
proved over the decades. This can be attributed to advances
in the surgical technique, perioperative and post-transplant
intensive care management, and the introduction of better
immunosuppressive drugs. Thus, there has been a constant
evolution in the indications and contraindications for liver
transplantation.Betterscoringsystemshavebeenintroduced
to select patients and allocate organs in DDLT programs.
Living donor transplantation has been introduced to over-
come the gap between the need and availability of deceased
donor organs especially in countries where deceased organ
donation is rare. It oﬀers deﬁnite advantage in situations
where the waiting period otherwise would be lengthy and
where entry to the waiting list for a DDLT would be
restricted.
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